Davis, Ian D <br/><br/>
An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Jun 2007 
 - 3630-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-07-0410  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Granzymes--drug effects<br/>Humans<br/>Interleukin-2 Receptor alpha Subunit--blood<br/>Interleukins--administration & dosage<br/>Male<br/>Maximum Tolerated Dose<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Perforin<br/>Pore Forming Cytotoxic Proteins--drug effects<br/>Recombinant Proteins--administration & dosage<br/>Interleukin-21